The global impact of vaccination against hepatitis B: a historical overview.
about
Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesisCurrent progress in the development of therapeutic vaccines for chronic hepatitis B virus infectionCationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccineVirus-induced hepatocellular carcinoma with special emphasis on HBV.Recent advances in micro/nanotechnologies for global control of hepatitis B infectionEpidemic history and evolutionary dynamics of hepatitis B virus infection in two remote communities in rural NigeriaPrevalence of hepatitis B virus seromarkers in young adults vaccinated at birth; impact on the epidemiology of hepatitis B infection in iran.A population-based study examining hepatitis B virus infection and immunization rates in Northwest ChinaOccult hepatitis B virus and hepatocellular carcinomaHepatitis B virus seroprevalence among Malawian medical students: A cross-sectional study.Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine.Factors affecting the introduction of new vaccines to poor nations: a comparative study of the Haemophilus influenzae type B and hepatitis B vaccines.Application of hepatitis B virus replication mouse modelView and review on viral oncology research.Costs and efficacy of public health interventions to reduce aflatoxin-induced human diseaseHepatitis B virus: where do we stand and what is the next step for eradication?Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production.Hepatitis B vaccine by intradermal route in non responder patients: an update.Modification of the hepatitis B virus envelope protein glycosylation pattern interferes with secretion of viral particles, infectivity, and susceptibility to neutralizing antibodies.Twenty years of universal vaccination against hepatitis B in Italy: achievements and challenges.The impact of immigration and vaccination in reducing the incidence of hepatitis B in Catalonia (Spain).Hepatitis B screening practice among older Chinese in the Greater Washington, DC, area.Is universal HBV vaccination of healthcare workers a relevant strategy in developing endemic countries? The case of a university hospital in NigerThe Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.Factors associated with alcohol consumption in hepatitis B carriers: a nationwide study in the Republic of Korea.Chronic Schistosoma japonicum infection reduces immune response to vaccine against hepatitis B in mice.Viruses and human cancer: from detection to causality.Solution structure and in silico binding of a cyclic peptide with hepatitis B surface antigen.Hepatitis B vaccination and associated oral manifestations: a non-systematic review of literature and case reports.Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial.High burden of hepatitis B infection in Northern Uganda: results of a population-based survey.Occult hepatitis B virus infection in anti-HBs-positive infants born to HBsAg-positive mothers in China.Gestational zinc deficiency impairs humoral and cellular immune responses to hepatitis B vaccination in offspring mice.Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity regionEfficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation programValidation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection.Ongoing transmission of hepatitis B virus in rural parts of the Netherlands, 2009-2013Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccineThe long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in ItalyLower mutation frequency of BCP/precore regions in e antigen-negative chronic HBV-infected children instead of adults patients.
P2860
Q26823512-F5D8CD39-0259-4CCE-B131-0A019ADBD4C8Q28076279-696E3C54-4A15-4ADB-B80E-55CE2D0CCB1FQ28656316-0DCE2F4B-2261-4F06-BC28-AD7ACDA1EBDDQ30238961-5F649406-1097-4150-885F-38DC0028DCE3Q30394611-CE344B85-1EAE-45BF-A9C3-0FA85A66FD0BQ33349504-B1CC83A1-BF77-4F01-9C39-149B4F9CA742Q33580024-93CEE4B6-F2E4-465D-8E81-BCEB574455DFQ33618408-9D41A750-324E-4F9E-A489-AE22159A04C3Q33661018-9DE827A1-CA94-4B76-AFCF-5F14922825A3Q33721413-2C1D4A74-E3B4-4D18-B12D-6FB02EA18EA1Q33724413-85546756-126F-4CCD-A9BA-074EBF5E236BQ33745105-F5262F27-AD6A-4EC2-8C25-D2956E9BF994Q33812160-18155B78-96CB-4D6B-ABF2-10AB905DA59FQ33894872-82A50D44-E990-4395-AF50-CFACE7445440Q33912791-111E99C6-E2C4-40B5-91DA-7DEED21DA469Q33958764-9D9ECA7E-C95D-46A9-BDD2-B3E19986DA3EQ34034063-A913D6F6-8DFE-4D91-9CE2-99AB283C7A81Q34036643-73B3C2AF-FE33-4B48-AFFE-0363CA812373Q34059278-0B66D465-0EAD-4B50-AE88-72EAF5804819Q34074115-A5207804-7E46-4D75-A396-D6BEB4F5E9FBQ34367717-84266973-1DF2-4443-86D1-FDDBAC42A9F4Q34383363-6B42B50D-EFE9-480A-BB87-9541507A9731Q34412410-8945D37E-1FFC-4592-9BA6-57CFD2F72BFDQ34481429-B99B9A5F-AB1F-4245-A666-5DD32842C0CEQ34489138-4120BB6D-5EF3-4F3B-8721-736B545C69A2Q34525309-45E015B5-DE3C-4363-A8D5-E34AA13D746BQ34567612-2EB6B9DF-2A46-4ACD-AED8-FD39308F6674Q34584862-710B5DFD-4810-47F2-AFCB-31DBE54ACA80Q34606667-E19A9F61-F907-42A7-A6DF-7F69CF59D20BQ34789906-4DE22E99-AA59-4CF8-AB71-29979064B5AAQ34899224-F27A56B4-8A6B-43C0-BE35-FE6AF06479E0Q34947605-34BD4514-C625-4402-9995-7A7626F38869Q34998696-43FAEFAE-7298-4788-9D72-A42943600E52Q35033602-AE84CBA3-8F54-4191-B070-82838BA9B1E0Q35084497-3F547517-2E3C-4D1B-8178-C73AF942A1D8Q35097179-4F2DE8D3-0C97-4EA8-8470-17DA8E16E08EQ35112543-4909A6D6-D6E6-41BE-9C94-312E473C34EDQ35191198-24A17EE7-9543-405A-AB6B-D27456C88B2FQ35224155-B4FBE2FF-DEA3-4BA8-A833-CA75034B8121Q35231699-EA215137-71E3-4A37-B6E1-CB8CEACF65BB
P2860
The global impact of vaccination against hepatitis B: a historical overview.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The global impact of vaccination against hepatitis B: a historical overview.
@en
The global impact of vaccination against hepatitis B: a historical overview.
@nl
type
label
The global impact of vaccination against hepatitis B: a historical overview.
@en
The global impact of vaccination against hepatitis B: a historical overview.
@nl
prefLabel
The global impact of vaccination against hepatitis B: a historical overview.
@en
The global impact of vaccination against hepatitis B: a historical overview.
@nl
P1433
P1476
The global impact of vaccination against hepatitis B: a historical overview.
@en
P2093
Alessandro R Zanetti
Daniel Shouval
P304
P356
10.1016/J.VACCINE.2008.09.056
P407
P577
2008-10-09T00:00:00Z